{"denoms":[{"counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"35"},{"groupId":"BG004","value":"60"},{"groupId":"BG005","value":"120"},{"groupId":"BG006","value":"33"},{"groupId":"BG007","value":"377"}],"units":"Participants"}],"groups":[{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"BG000","title":"Relapsed Myeloma (<4 Prior Regimens): Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"BG001","title":"Lenalidomide Refractory Myeloma: Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"BG002","title":"Bortezomib/Lenalidomide Refractory/Relapsed Myeloma: Low Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"BG003","title":"Bortezomib/Lenalidomide Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"BG004","title":"Relapsed Myeloma (< 4 Prior Regimens): High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"BG005","title":"Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"BG006","title":"Relapsed Amyloidosis: Low Dose"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"35","upperLimit":"88","value":"65.5"},{"groupId":"BG001","lowerLimit":"39","upperLimit":"77","value":"61.5"},{"groupId":"BG002","lowerLimit":"39","upperLimit":"77","value":"62"},{"groupId":"BG003","lowerLimit":"45","upperLimit":"77","value":"61"},{"groupId":"BG004","lowerLimit":"32","upperLimit":"82","value":"65.5"},{"groupId":"BG005","lowerLimit":"36","upperLimit":"85","value":"65"},{"groupId":"BG006","lowerLimit":"52","upperLimit":"82","value":"66"},{"groupId":"BG007","lowerLimit":"32","upperLimit":"88","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"47"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"138"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"40"},{"groupId":"BG005","value":"73"},{"groupId":"BG006","value":"19"},{"groupId":"BG007","value":"239"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"35"},{"groupId":"BG004","value":"60"},{"groupId":"BG005","value":"120"},{"groupId":"BG006","value":"33"},{"groupId":"BG007","value":"377"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}